Literature DB >> 6690060

Comparison of virus reactivation, DNA base damage, and cell cycle effects in autologous human melanoma cells resistant to methylating agents.

I P Hayward, P G Parsons.   

Abstract

A human melanoma cell line (MM253c1-3D) having an induced stable resistance to the methylating agents 5-(3'-methyl-1-triazeno)imidazole-4-carboxamide, methylnitrosourea, and N-methyl-N'-nitro-N-nitrosoguanidine gave more efficient replication of 5-(3'-methyl-1-triazeno)imidazole-4-carboxamide-treated adenovirus 5 than did the methylation-sensitive parent line (MM253c1). Analysis of DNA hydrolysates from melanoma cells treated with [3H]methylnitrosourea for 1.6 hr showed similar initial levels of 7-methylguanine and 3-methyladenine in both cell lines and substantial excision of the latter lesion after 19 hr. O6-Methylguanine in the DNA of MM253c1 cells also decreased during this period, but in MM253c1-3D cells the initial yield of this lesion was too low for subsequent decrease to be detected. 5-(3'-Methyl-1-triazeno)imidazole-4-carboxamide induced a significant arrest of MM253c1 cells in the G2 phase of the cell cycle. These results show that MM253c1 is a variant of the Mer- phenotype, the resistance of MM253c1-3D cells being attributed to reversion to Mer+ and expressed as very rapid repair of O6-methylguanine lesions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690060

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  J M Carethers; M T Hawn; D P Chauhan; M C Luce; G Marra; M Koi; C R Boland
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Cell cycle perturbation and cell death after exposure of a human lymphoblastoid cell strain to N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  K A Black; R D McFarland; J W Grisham; G J Smith
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

3.  KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation.

Authors:  Lynn M Hassman; Thomas J Ellison; Dean H Kedes
Journal:  J Clin Invest       Date:  2011-01-18       Impact factor: 14.808

4.  In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.

Authors:  S M Lee; N Thatcher; D Crowther; G P Margison
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Host cell reactivation of gamma-irradiated adenovirus 5 in human cell lines of varying radiosensitivity.

Authors:  J J Eady; J H Peacock; T J McMillan
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

6.  Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

Authors:  S M Lee; N Thatcher; M Dougal; G P Margison
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

7.  Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide.

Authors:  J M Lunn; A L Harris
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

8.  Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma.

Authors:  S M Lee; J A Rafferty; R H Elder; C Y Fan; M Bromley; M Harris; N Thatcher; P M Potter; H J Altermatt; T Perinat-Frey
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

9.  Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.

Authors:  S M Lee; G P Margison; N Thatcher; P J O'Connor; D P Cooper
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

10.  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.

Authors:  S R Wedge; J K Porteus; B L May; E S Newlands
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.